Trials / Completed
CompletedNCT01128439
Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease
A Postmarketing Observational Study Estimating The Impact Of Prevnar 13 (Trade Mark) (13vpnc) On Invasive Pneumococcal Disease Caused By Vaccine Serotypes Of Streptococcus Pneumoniae After Introduction Into Routine Pediatric Use
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study will estimate the incidence of invasive pneumococcal disease in members of the Northern Kaiser Permanente healthcare system during each of the 5 following introduction of Prevnar 13.
Detailed description
No sampling as no subjects are enrolled
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | No intervention |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2015-04-01
- Completion
- 2015-04-01
- First posted
- 2010-05-21
- Last updated
- 2018-12-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01128439. Inclusion in this directory is not an endorsement.